Polaris Group, a privately held multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases in humans.

Polaris' lead project is ADI-PEG 20, a biotherapeutic agent that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma.

Polaris is collaborating with EnzymeRx in the development of Uricase-PEG 20 for the treatment of gout, tumor lysis syndrome, and other diseases related to hyperuricemia.

Polaris is also researching and developing other biotherapeutic agents and has a small molecule drug program. The latter utilizes a rational structure-based approach for the design of novel compounds that inhibit the biological function of cancer-related protein targets.

Biotechnology

Pharmaceutical

Polaris Pharmaceuticals

Polaris Pharmaceuticals' headquarters in San Diego, CA, United States

Description

People (10)

Shaw T. Chen

Bharat C.

Eric Van Rumund

Richard E. Showalter

Mariusz Stempniak

Soneprasith "Ham" Phonephaly

Stephanie Van Rumund, BSRT

Tanja Nielsen, Dr. rer. nat.

Wei-Jong Shia

Nicole Deford

Jobs